Korea Pharma한국파마
032300 · KOSDAQ · ₩032300 · 한국파마
₩8,170 ₩0 (0.00%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 35.9% | 35.8% | 43.3% | 44.4% | 43.7% | 45.1% |
| Operating margin | 1.8% | −1.0% | 7.5% | 7.5% | 7.6% | 6.3% |
| Net margin | −1.0% | −3.0% | 4.7% | 0.1% | −1.4% | 8.0% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +7.2% | +7.8% | −2.4% | +2.7% | +1.8% | — |
| Operating income growth | +288.2% | −114.6% | −2.9% | +1.3% | +23.4% | — |
| Net income growth | +64.3% | −169.6% | +4,426.7% | +107.5% | −117.6% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −1.3% | −3.8% | 5.4% | 0.1% | −1.9% | 11.1% |
| Return on assets | −0.7% | −2.2% | 3.2% | 0.1% | −0.9% | 4.9% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 77.3% | 84.1% | 57.3% | 76.9% | 118.9% | 125.2% |
| Net debt to equity | 0.5% | 14.6% | −22.7% | −10.8% | −14.6% | −6.0% |
| Current ratio | 158.2% | 113.8% | 381.1% | 256.4% | 141.1% | 381.3% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Korea Pharma / 한국파마 / 032300 / KRX:032300
Source: KRX statistical information